Literature DB >> 34011747

Immediate sequential bilateral cataract surgery and its relevance in COVID-19 era.

Jatinder S Bhalla1, Mohmad Uzair Zakai1, Amit Mehtani1.   

Abstract

Immediately sequential bilateral cataract surgery (ISBCS) involves performing phacoemulsification with intraocular lens implantation in both the eyes of a patient, sequentially in the same operative sitting. There are well-documented advantages in terms of quicker visual rehabilitation and reduced costs. The risk of bilateral simultaneous endophthalmitis and bilateral blindness is now recognized to be minuscule with the advent of intracameral antibiotics and modern management of endophthalmitis. Refractive surprises are rare for normal eyes and with the use of optical biometry. As a result of the COVID-19 pandemic, all elective surgeries were stopped. This has resulted in a large backlog of deferred cataract surgeries. Now more than ever before, we should consider ISBCS as an excellent alternative to delayed sequential bilateral cataract surgery in the right hospital or surgical setting. In the age of COVID-19, it can help to decrease surgical scheduling and follow-up visits. The one change in practice that could have the most significant benefit in reducing infection exposure risk is ISBCS.

Entities:  

Keywords:  Bilateral cataract surgery; COVID-19; ISBCS; SBCS

Year:  2021        PMID: 34011747     DOI: 10.4103/ijo.IJO_3586_20

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  2 in total

1.  A Systematic Review of the Effects of Second-Eye Cataract Surgery on Motor Function.

Authors:  William E A Sheppard; Dane McCarrick; Richard M Wilkie; Rigmor C Baraas; Rachel O Coats
Journal:  Front Aging       Date:  2022-06-22

2.  Ophthalmologists' attitudes toward immediate sequential bilateral cataract surgery: Dutch national survey.

Authors:  Lindsay S Spekreijse; Claudette A Veldhuizen; Ype P Henry; Frank J H M van den Biggelaar; Carmen D Dirksen; Rudy M M A Nuijts
Journal:  J Cataract Refract Surg       Date:  2022-02-25       Impact factor: 3.528

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.